Outlook For the remainder of 2017, the Company expects:
• FY 2017 revenues from product sales to exceed analysts’ forecasts and for the fourth quarter results to exceed the third quarter significantly, driven by underlying increasing demand
• Achievement of continued operating profit and positive cashflows for the remaining quarter
• Continued investment in the production of RUCONEST® in order to ensure continuity of supply to the growing markets in the US, Europe and the RoW
• Investment in the approval for RUCONEST® in prophylaxis of HAE and in further clinical trial development of a small, fast IV version and new intramuscular, subcutaneous and other delivery options for RUCONEST®
• Continued and enhanced support for patients in all territories, as we continue to believe that RUCONEST® represents a fast, effective, reliable and safe therapy option available to HAE patients
• Continued progress in the new pipeline programs in Pompe disease and Fabry’s disease, and additional development opportunities and assets as they occur